Last reviewed · How we verify

IPTp-sulphadoxine-pyrimethamine

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

IPTp-sulphadoxine-pyrimethamine is a Antifolate antimalarial combination Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Malaria prevention in pregnant women (Intermittent Preventive Treatment in pregnancy), Malaria treatment and chemoprophylaxis. Also known as: Fansidar.

Sulphadoxine-pyrimethamine is an antimalarial combination that inhibits dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in Plasmodium parasites.

Sulphadoxine-pyrimethamine is an antimalarial combination that inhibits dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in Plasmodium parasites. Used for Malaria prevention in pregnant women (Intermittent Preventive Treatment in pregnancy), Malaria treatment and chemoprophylaxis.

At a glance

Generic nameIPTp-sulphadoxine-pyrimethamine
Also known asFansidar
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntifolate antimalarial combination
TargetDihydrofolate reductase; Dihydropteroate synthase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Parasitology
PhasePhase 3

Mechanism of action

The drug combination works synergistically: pyrimethamine inhibits dihydrofolate reductase while sulphadoxine inhibits dihydropteroate synthase, both enzymes critical for parasite folate metabolism. This dual inhibition prevents DNA synthesis and replication in malaria parasites. IPTp (Intermittent Preventive Treatment in pregnancy) uses this combination as chemoprophylaxis to prevent malaria infection during pregnancy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IPTp-sulphadoxine-pyrimethamine

What is IPTp-sulphadoxine-pyrimethamine?

IPTp-sulphadoxine-pyrimethamine is a Antifolate antimalarial combination drug developed by London School of Hygiene and Tropical Medicine, indicated for Malaria prevention in pregnant women (Intermittent Preventive Treatment in pregnancy), Malaria treatment and chemoprophylaxis.

How does IPTp-sulphadoxine-pyrimethamine work?

Sulphadoxine-pyrimethamine is an antimalarial combination that inhibits dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in Plasmodium parasites.

What is IPTp-sulphadoxine-pyrimethamine used for?

IPTp-sulphadoxine-pyrimethamine is indicated for Malaria prevention in pregnant women (Intermittent Preventive Treatment in pregnancy), Malaria treatment and chemoprophylaxis.

Who makes IPTp-sulphadoxine-pyrimethamine?

IPTp-sulphadoxine-pyrimethamine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is IPTp-sulphadoxine-pyrimethamine also known as anything else?

IPTp-sulphadoxine-pyrimethamine is also known as Fansidar.

What drug class is IPTp-sulphadoxine-pyrimethamine in?

IPTp-sulphadoxine-pyrimethamine belongs to the Antifolate antimalarial combination class. See all Antifolate antimalarial combination drugs at /class/antifolate-antimalarial-combination.

What development phase is IPTp-sulphadoxine-pyrimethamine in?

IPTp-sulphadoxine-pyrimethamine is in Phase 3.

What are the side effects of IPTp-sulphadoxine-pyrimethamine?

Common side effects of IPTp-sulphadoxine-pyrimethamine include Gastrointestinal disturbances, Rash, Folate deficiency, Stevens-Johnson syndrome (rare).

What does IPTp-sulphadoxine-pyrimethamine target?

IPTp-sulphadoxine-pyrimethamine targets Dihydrofolate reductase; Dihydropteroate synthase and is a Antifolate antimalarial combination.

Related